[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"huntington-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:huntington-disease":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,44,0,25,[9,51,82,95,118,131,155,188,217,265,289,312,334,367,394,419,446,473,493,538,565,586,611,637,664],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100053454","phase-3-a-study-to-investigate-the-efficacy-safety-and-tolerability-of-votoplam-in-participants-with-huntingtons-disease-100053454",false,"NCT07326709","A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease","A Randomized, Placebo-controlled, Double-blind Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease","INVEST-HD","Inclusion Criteria:\n\n* Signed informed consents must be obtained prior to participation in the study\n* Ambulatory male or female participants between 21 to 70 years of age, inclusive, on the day of Informed Consent signature\n* Genetically confirmed HD diagnosis with a cytosine-adenine-guanine (CAG) repeat length of 40 or above. Participants must have prior genetic confirmation and known CAG repeat length obtained prior to screening.\n* Meets all of the following criteria:\n\n  * UHDRS IS score ≥90\n  * UHDRS TFC score = 13\n  * UHDRS TMS score = 7-25, inclusive\n  * CAP100 ≥ 70 Calculation: CAP = Age at study entry × (CAG length - 30) \u002F 6.49\n\nExclusion Criteria:\n\n* History of gene therapy or cell transplantation or any other experimental brain surgery for the treatment of HD\n* Serologic evidence for active viral hepatitis as indicated by:\n\n  * positive anti-HBc IgM\n  * positive anti-HBc IgG confirmed by positive HBsAg and\u002For HBV DNA\n  * positive HCV ab test confirmed by positive HCV RNA\n  * Immunodeficiency diseases, including a positive human immunodeficiency virus (HIV) test result\n* History or current diagnosis of ECG or cardiac abnormalities indicating significant risk of safety for participants such as:\n\n  * Concomitant clinically significant cardiac arrhythmias, e.g., sustained ventricular tachycardia, and clinically significant second- or third-degree AV block without a pacemaker\n  * History of familial long QT syndrome or known family history of Torsade de Pointes\n* Women of childbearing potential, defined as all women physiologically capable of becoming pregnant from menarche until becoming post-menopausal, unless they have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or bilateral salpingectomy at least six weeks before taking study treatment. In the case of oophorectomy alone, the reproductive status of the woman needs to have been confirmed by follow-up hormone level assessment.\n\n  o WOCBP are excluded unless they are using highly effective methods of contraception (failure rate \\\u003C 1% per year) while taking study treatment and for 8 months after stopping study treatment.\n* Pregnant or nursing (breastfeeding) women\n\nOther protocol defined inclusion\u002Fexclusion criteria may apply","ALL","21 Years","70 Years",{"count":22,"type":23},770,"ESTIMATED","INTERVENTIONAL",[26],"PHASE3","The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm.\n\nHTT227 - current compound code (former code is PTC518 from PTC Therapeutics), HTT227 is Novartis code under Novartis sponsorship.",[29],"Huntington Disease",[31,16,32,33,34,35,36,37],"HD","HTT227","VOTOPLAM","HUNTINGTON DISEASE","UHDRS","mHTT","NfL","RECRUITING","2026-07-09",{"date":41,"type":42},"2026-07-13","ACTUAL",{"date":44,"type":42},"2026-03-24",{"date":46,"type":23},"2030-04-30",{"name":48,"class":49},"Novartis Pharmaceuticals","INDUSTRY",41,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":24,"phases":62,"briefSummary":64,"conditions":65,"keywords":66,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":74,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100053987","phase-2-study-to-evaluate-the-pharmacodynamics-safety-and-efficacy-of-sky-0515-in-participants-with-huntingtons-disease-100053987","NCT07378644","Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease","A Phase 2\u002F3 Randomized, Double Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease","FALCON-HD","Inclusion Criteria:\n\n* 25 years or older.\n* Huntington's Disease confirmed through genetic testing, with a specific change in exon 1 of the HTT gene (CAG repeat of 40 or more).\n* Total Functional Capacity (TFC) score of 10 or more).\n* Total Motor Score (TMS) of 6 or more).\n* Independence Score (IS) of 70 or more).\n* Women who can have children must have a negative pregnancy test before starting and use two types of birth control during the study and for 30 days after the last dose of the study drug.\n* Men must agree to use birth control during the study and for 90 days after the last dose.\n* Agree to sign a consent form and follow the study's rules and schedule.\n\nExclusion Criteria:\n\n* Other Serious health problems or brain\u002Fspinal issues that could interfere with the study or make procedures unsafe.\n* Conditions that interfere with protocol-specified assessments, like an implanted medical device or difficulty getting an MRI.\n* Cancer, except for some types of skin cancer, or a history of cancer in the last five years.\n* Severe allergies or have reacted badly to similar drugs in the past.\n* Taking medications or treatments that might interfere with the study.\n* Participated in another study or taken experimental drugs in the last two months (or longer for some drugs).\n* Any kind of gene therapy.\n* History of suicidal thoughts, severe depression, or have attempted suicide in the past year.\n* Liver function tests show significant abnormalities.\n* Positive for hepatitis B, hepatitis C, or HIV.\n* Pregnancy, breastfeeding, or planning to become pregnant during the study.","25 Years",{"count":61,"type":23},400,[63,26],"PHASE2","The goal of this clinical trial is to test if the drug SKY-0515, an oral medication, can lower harmful proteins linked to Huntington's Disease (HD) and improve the symptoms of participants with HD. This study includes men and women aged 25 and older who have HD confirmed by genetic testing and meet certain requirements for physical ability and independence.",[29],[67,68,69,70,29,71,72,73],"SKY-0515","Skyhawk","HTT","Neurodegenerative","mRNA","Splicing","Mutant Huntingtin protein",{"date":41,"type":42},{"date":76,"type":42},"2026-01-06",{"date":78,"type":23},"2029-08",{"name":80,"class":49},"Skyhawk Therapeutics, Inc.",19,{"id":83,"slug":4,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":24,"phases":85,"briefSummary":64,"conditions":86,"keywords":87,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":92,"leadSponsor":93,"locationsCount":94},"100622055",{"count":61,"type":23},[63,26],[29],[67,68,69,70,29,71,72,73],"2026-06-30",{"date":90,"type":42},"2026-07-01",{"date":76,"type":42},{"date":78,"type":23},{"name":80,"class":49},10,{"id":96,"slug":97,"hasResults":12,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":117},"100567378","frequency-of-selected-single-nucleotide-polymorphisms-in-huntington-disease-gene-expansion-carriers-100567378","NCT06667414","Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers","Frequency of Selected Single Nucleotide Polymorphisms in Phase With the Mutant and Wild-Type HTT Alleles in Huntington Disease Gene Expansion Carriers","Inclusion Criteria:\n\n* Have signed the Informed Consent Form (ICF)\n* Aged 25 to 60 years, inclusive, at the time of signing the ICF\n* Confirmation of Huntington Disease (HD) gene expansion mutation carrier status\n* Confirmation of Total Functional Capacity (TFC) ≥9 and Total Motor Score (TMS) \\>6 within 12 months prior to signing the ICF\n* Ability to tolerate blood draws\n\nExclusion Criteria:\n\n* None","60 Years",{"count":104,"type":23},600,"OBSERVATIONAL","For participation in this epidemiological study, a single-day visit at the study site is required. Participants will be recruited from Huntington Disease clinics, and they will be asked to answer questions regarding their demographics, including sex, age, race and ethnicity, and their medical and medication history. At the end of the visit, a blood sample will be drawn to allow testing with a sequencing assay that is specifically designed for phasing single nucleotide polymorphisms (SNPs) on the wild-type Huntington (wtHTT) and mutant Huntington (mHTT) alleles.",[29],"2026-06-26",{"date":110,"type":42},"2026-06-29",{"date":112,"type":42},"2024-09-02",{"date":114,"type":23},"2027-02-28",{"name":116,"class":49},"Hoffmann-La Roche",45,{"id":119,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":120,"targetDuration":4,"studyType":24,"phases":121,"briefSummary":27,"conditions":122,"keywords":123,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":128,"leadSponsor":129,"locationsCount":130},"100618060",{"count":22,"type":23},[26],[29],[31,16,32,33,34,35,36,37],"2026-06-19",{"date":126,"type":42},"2026-06-23",{"date":44,"type":42},{"date":46,"type":23},{"name":48,"class":49},27,{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":12,"sex":18,"minAge":139,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":24,"phases":142,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":4},"100637382","phase-3-pridopidine-phase-3-study-in-huntingtons-disease-100637382","NCT07609108","Pridopidine Phase 3 Study in Huntington's Disease","A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants With Huntington's Disease (HD)","PRECISE-HD","Inclusion Criteria:\n\n* Adult-onset HD (onset of signs and symptoms and a clinical diagnosis at ≥21 years of age).\n* A diagnosis based on clinical features and the presence of ≥40 CAG repeats in the huntingtin (HTT) gene confirmed by historical laboratory quanitified results or by a diagnostic test at Screening.\n* Diagnostic confidence level (DCL) of 4 (DCL=4 unequivocal motor signs, ≥99% confidence) on the standardized motor exam Total Motor Score (TMS).\n* Total Functional Capacity (TFC) score of ≥7 at Screening and Baseline.\n* Cytosine-Adenine-Guanine (CAG)-Age Product (CAP)100 score ≥95 at Screening.\n* Independence Scale (IS) score ≤90% at Screening.\n* Total Motor Score (TMS) of ≥20 at Screening and Baseline.\n* Not using ADMs (VMAT2i and neuroleptics\u002Fantipsychotics) for at least 6 months prior to Screening visit. Importantly, it is not encouraged to discontinue the participants' ADM treatment solely for enrollment in the current trial.\n\nExclusion Criteria:\n\n* Clinically significant cardiovascular disease (e.g. QTcF \\>450 msec \\[males\\] or \\>470 msec \\[females\\], arrhythmias, uncontrolled atrial fibrillation, or congenital long QT syndrome), seizure history ≤5 years, significant neurological disorders (e.g. intracranial pathology or cerebrovascular events), active\u002Frecent malignancy (unless localized and resolved), or any serious or uncontrolled systemic disease (e.g. hepatic, renal, respiratory, endocrine, infectious \\[HBV, HCV, HIV\\], or psychiatric) that may pose safety risk or interfere with participation.\n* Severe hepatic or renal impairment.\n* Any mutant huntingtin (mHTT) lowering therapy in the past year.\n* Medications that prolong QT interval, taken within 4 weeks of the baseline visit.\n* Use of pridopidine within 6 weeks or 5 half-lives before the screening visit.\n* Previous participation in intracranial gene therapy study.\n* Laboratory values that fall outside of the central laboratory's reference range at Screening and are considered clinically significantly abnormal by the Investigator and affect the participant's suitability to participate in the study or put the participant at risk if he\u002Fshe enters the study in the Investigator's opinion.\n* Female participants who are pregnant, planning to become pregnant or breastfeeding.","23 Years","65 Years",{"count":61,"type":23},[26],"The goal of this clinical trial is to learn if pridopidine can slow the clinical decline of Huntington's Disease (HD) in adult participants. It will also inform about the safety of pridopidine.\n\nThe main questions the study aims to answer are:\n\nDoes pridopidine slow the overall worsening of HD over 1 year? Does pridopidine slow the worsening of specific aspects of HD over 1 year, namely the clinical progression, the ability to perform daily life activities (functional capacity), the mind's ability to process information (cognition), working of the muscles (motor function), and quality of life?\n\nResearchers will compare the drug pridopidine to a placebo (a look-alike substance that contains no drug) to see if pridopidine works better than placebo to treat HD. During the first year of the study, participants will have the same chance to receive either pridopidine or placebo.\n\nParticipants will:\n\nTake 1 pridopidine or placebo capsule twice daily for 12 months. Visit the clinic 6 times within 1 year for checkups and tests.\n\nAll participants who complete this 1-year placebo-controlled study period will roll over into an additional 2-year study period during which all participants will receive pridopidine treatment, including participants who had received placebo during the first year. During this additional 2-year treatment period participants will visit the clinic a total of 6 times for checkups and tests.",[29],"NOT_YET_RECRUITING","2026-05-29",{"date":148,"type":42},"2026-06-02",{"date":150,"type":23},"2026-06",{"date":152,"type":23},"2030-06",{"name":154,"class":49},"Prilenia",{"id":156,"slug":157,"hasResults":12,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":140,"enrollmentInfo":162,"targetDuration":4,"studyType":24,"phases":164,"briefSummary":166,"conditions":167,"keywords":168,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":187},"100579616","phase-1-a-randomized-study-of-spk-10001-gene-therapy-in-participants-with-huntingtons-disease-100579616","NCT06826612","A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease","A Phase 1\u002F2, Randomized, Sequential, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of a One-Time, Bilateral, Intraparenchymal Infusion of SPK-10001 Into the Caudate and Putamen in Participants With Huntington's Disease","Key Inclusion Criteria:\n\n* Have confirmed huntingtin (HTT) cytosine-adenine-guanine (CAG) repeat length ≥40 on genetic testing and confirmation diagnostic test by the central laboratory (CL) at screening.\n* Have striatal atrophy demonstrated by caudate\u002Fintracranial volume less than the age-adjusted cutoff values associated with HDISS Stage 1.\n* Have UHDRS Total Motor Score (TMS) equal to or greater than the age-adjusted cutoff value associated with HDISS Stage 2.\n* Have UHDRS Total Functional Capacity (TFC) greater than or equal to 11.\n* Use of cholinesterase inhibitors, memantine, amantadine, or riluzole must have been at stable dosing for at least 12 weeks before screening and baseline and anticipated to remain stable during the first 12 months after SPK-10001 administration.\n* Antidepressant or benzodiazepine use must have been at stable dosing for at least 12 weeks before screening and baseline and anticipated to remain stable during the first 12 months after SPK-10001 administration.\n* Antipsychotics for motor symptoms or mood stabilization (i.e., irritability or aggressive behavior) and\u002For tetrabenazine, valbenazine, or deutetrabenazine must have been at a stable dose for at least 12 weeks before screening and baseline and are anticipated to remain stable during the first 12 months after SPK-10001 administration.\n\nKey Exclusion Criteria:\n\n* A safe trajectory is not able to be identified for targeting placement of the cannula into the caudate or putamen on both sides of the brain due to extent of atrophy or other anatomical features.\n* Have received an antisense oligonucleotide therapy during the past year.\n* History of deep brain stimulation.\n* History of or intention to undergo gene therapy, cell transplantation, or brain surgery during the course of the study.\n* Have participated in an investigational drug study with a systemic administration within 6 weeks or 5 half-lives of screening, whichever is longer.\n\nAdditional protocol-defined inclusion\u002Fexclusion criteria apply.",{"count":163,"type":23},53,[165,63],"PHASE1","The main goal of this study is to evaluate the safety, tolerability, and preliminary efficacy of SPK-10001 in participants with Huntington's Disease.",[29],[169,170,171,31,172,173,174,175,176,177,178,36],"Huntington's Disease","SPK-10001","Adult-onset HD","Rare Disease","Chorea","Movement Disorder","Spark Therapeutics","Cognition","Gene Therapy","AAV","2026-04-29",{"date":181,"type":42},"2026-05-05",{"date":183,"type":42},"2025-02-21",{"date":185,"type":23},"2035-01-12",{"name":116,"class":49},5,{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":12,"sex":18,"minAge":195,"maxAge":196,"enrollmentInfo":197,"targetDuration":4,"studyType":24,"phases":199,"briefSummary":201,"conditions":202,"keywords":203,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":216},"100632450","optimizing-parameters-of-low-intensity-focused-ultrasound-for-pallidal-modulation-in-huntingtons-disease-100632450","NCT07513844","Optimizing Parameters of Low-Intensity Focused Ultrasound for Pallidal Modulation in Huntington's Disease","Low-Intensity Focused Ultrasound Stimulation of the External Globus Pallidus in Huntington's Disease: A Phase I\u002FII Safety and Feasibility Trial","Inclusion Criteria:\n\n1. Aged 18 to 75 years (inclusive)\n2. Genetically confirmed Huntington's disease with HTT CAG repeat length of 40 or greater\n3. Unified Huntington's Disease Rating Scale Total Maximal Chorea score of 8 or higher on a scale of 0 to 28, with higher scores indicating more severe chorea\n4. Huntington's Disease Integrated Staging System stage 2 or 3\n5. Willing to participate and provide informed consent\n6. Have a reliable caregiver available\n7. No severe cognitive impairment that would preclude reliable reporting of adverse events or efficacy during treatment\n\nExclusion Criteria:\n\n1. History of self-injury, aggressive behavior, or unstable psychiatric disorders\n2. History of head injury or neurosurgical procedure\n3. Presence of intracranial implants, metallic foreign bodies, cochlear implants, or cardiac pacemakers\n4. Severe systemic disease, pregnancy, or breastfeeding\n5. Contraindications to magnetic resonance imaging, ultrasound, or anesthesia\n6. Prior treatment with electroconvulsive therapy, transcranial magnetic stimulation, transcranial direct current stimulation, transcranial alternating current stimulation, or other neuromodulation therapies within the past 3 years\n7. Severe brain atrophy with unclear external globus pallidus structure on MRI\n8. Concurrent participation in another interventional clinical trial\n9. Any other condition that, in the opinion of the investigator, would preclude participation","18 Years","75 Years",{"count":198,"type":23},24,[200],"NA","The purpose of this research study is to determine the optimal pulse repetition frequency of low-intensity focused ultrasound that is safe and effective in improving motor symptoms in patients with Huntington's disease.",[29],[204,29,205,206],"low intensity focused ultrasound","brain stimulation","ultrasonic stimulation","2026-04-23",{"date":179,"type":42},{"date":210,"type":42},"2026-04-20",{"date":212,"type":23},"2027-03-31",{"name":214,"class":215},"First Affiliated Hospital of Fujian Medical University","OTHER",1,{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":12,"sex":225,"minAge":195,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":228,"conditions":229,"keywords":244,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":258,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":216},"100527411","development-of-non-invasive-prenatal-diagnosis-for-single-gene-disorders-100527411","NCT06147414","Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders","Evaluation of the Diagnostic Performance of Non-Invasive Prenatal Diagnosis for Single Gene Disorders","DANNIgene","Inclusion Criteria:\n\n* pregnant woman with 9 weeks of amenorrhea or more\n* singleton pregnancy\n* undergoing invasive PND in a context of family history of SGD involving the following genes : HBB, CFTR, FMR1, SMN1, DMPK, DMD, NF1, HTT, F8, F9, GCK, L1CAM, PKHD1, or undergoing prenatal counselling in a context of maternal history of diabetes MODY-GCK\n* germinal pathogenic paternal and\u002For maternal mutations previously identified\n* age 18 years old or over\n* signing an informed consent\n\nExclusion Criteria:\n\n* at risk of SGD involving a de novo pathogenic mutation in a previous child\n* woman under legal protection","FEMALE",{"count":227,"type":23},550,"Cell-free fetal DNA (cffDNA) is present in the maternal blood from the early first trimester of gestation and makes up 5%-20% of the total circulating cell-free DNA (cfDNA) in maternal plasma. Its presence in maternal plasma has allowed development of noninvasive prenatal diagnosis for single-gene disorders (SGD-NIPD). This can be performed from 9 weeks of amenorrhea and offers an early, safe and accurate definitive diagnosis without the miscarriage risk associated with invasive procedures. One of the major difficulties is distinguishing fetal genotype in the high background of maternal cfDNA, which leads to several technical and analytical challenges. Besides, unlike noninvasive prenatal testing for aneuploidy, NIPD for monogenic diseases represent a smaller market opportunity, and many cases must be provided on a bespoke, patient- or disease-specific basis. As a result, implementation of SGD-NIPD remained sparse, with most testing being delivered in a research setting.\n\nThe present project aims to take advantage of the unique French collaborative network to make SGD-NIPD possible for theoretically any monogenic disorder and any family.",[230,231,232,233,234,235,236,237,238,29,239,240,241,242,243],"Invasive PreNatal Diagnosis in a Context of Family History of Single-gene Disorders, Including","Sickle Cell Disease","Cystic Fibrosis","Fragile X Syndrome","Proximal Spinal Muscular Atrophy","Myotonic Dystrophy","Muscular Dystrophy, Duchenne","Muscular Dystrophy, Becker","Neurofibromatosis-Noonan Syndrome","Hemophilia A","Hemophilia B","MODY2 Diabetes","X-Linked Hydrocephalus","Autosomal Recessive Polycystic Kidney Disease",[245,246,247,248,249,250,251,252,253,254,255,256,257],"Gene HBB","Gene CFTR","Gene FMR1","Gene SMN1","Gene DMPK","Gene DMD","Gene NF1","Gene HTT","Gene F8","Gene F9","Gene GCK","Gene L1CAM","Gene PKHD1",{"date":207,"type":42},{"date":260,"type":42},"2024-10-23",{"date":262,"type":23},"2027-05",{"name":264,"class":215},"Assistance Publique - Hôpitaux de Paris",{"id":266,"slug":267,"hasResults":12,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":12,"sex":18,"minAge":195,"maxAge":140,"enrollmentInfo":273,"targetDuration":4,"studyType":24,"phases":275,"briefSummary":276,"conditions":277,"keywords":278,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":285,"leadSponsor":287,"locationsCount":216},"100627667","phase-1-safety-and-tolerability-study-of-human-neural-stem-cells-for-huntingtons-disease-100627667","NCT07451613","Safety and Tolerability Study of Human Neural Stem Cells for Huntington's Disease","Phase 1B\u002F2A Study of the Safety and Tolerability of Human Neural Stem Cells for Huntington's Disease","REGEN4HD","Please note this may not be a complete list of eligibility criteria.\n\nInclusion Criteria:\n\n* Have decision-making capacity and be able to provide written informed consent.\n* Are between 18 to 65 years of age\n* Have genetically confirmed diagnosis of Huntington's Disease\n* Able to undergo MRI scans, tolerate neurosurgical procedure, blood draws and lumbar puncture.\n\nExclusion Criteria:\n\n* Are pregnant\n* Test positive for human immunodeficiency virus (HIV), hepatitis C or chronic hepatitis B at Screening\n* Have an implanted deep brain stimulation device.",{"count":274,"type":23},21,[165,63],"The purpose of this research study is to determine whether an implantation of hNSC-01 is a safe and tolerable study intervention for Huntington's disease. This study is the first time that hNSC-01 is being tested in people.",[29],[279,280,271],"Huntington's disease","stem cell","2026-04-06",{"date":283,"type":42},"2026-04-13",{"date":281,"type":42},{"date":286,"type":23},"2031-01",{"name":288,"class":215},"Leslie Thompson",{"id":290,"slug":291,"hasResults":12,"nctId":292,"briefTitle":293,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":295,"sex":296,"minAge":195,"maxAge":297,"enrollmentInfo":298,"targetDuration":4,"studyType":24,"phases":300,"briefSummary":301,"conditions":302,"keywords":4,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":216},"100632685","phase-1-mass-balance-study-of-14c-lpm3770164-in-healthy-participants-100632685","NCT07516899","Mass Balance Study of [14C] LPM3770164 in Healthy Participants","Inclusion Criteria:\n\n1. Healthy adult Chinese males;\n2. Age at informed consent: 18-45 years (including boundary value);\n3. Body mass index (BMI) range of 19-26 kg\u002Fm2 (including the boundary value), and body weight of not less than 50 kg;\n4. There is no plan to have children or donate sperm within 1 year after the participant signs the informed consent form and the participant voluntarily takes strict contraceptive measures within 1 year after signing the informed consent form and completing the trial;\n5. Fully understand the purpose and requirements of this study, and voluntarily sign the informed consent form;\n6. Able to communicate well with the investigators and be able to complete the trial according to the protocol.\n\nExclusion Criteria:\n\n1. Abnormal and clinically significant vital signs, physical examination, chest X-ray (anteroposterior), ophthalmic examination, anal digital examination and abdominal B ultrasound examination;\n2. Abnormal laboratory examination during the screening period, and clinically significant according to the investigator's judgment:\n3. QTcF interval \\> 450 ms in men; or other abnormalities are clinically significant in the judgment of the investigator;\n4. Abnormal tests of hepatitis B surface antigen, hepatitis C virus antibody IgG (Anti-HCV IgG), treponema pallidum antibody and human immunodeficiency virus antibody are clinically significant at the investigator's discretion;\n5. Use of any prescription drugs, over-the-counter drugs, Chinese herbal medicine, food supplements within 4 weeks prior to screening;\n6. Use of any drugs that inhibit or induce hepatic drug metabolizing enzyme activity within 4 weeks prior to screening;\n7. History of any clinically significant disease or disease or condition that may affect the results of the trial;\n8. History of organic heart disease, heart failure, myocardial infarction, angina pectoris, unexplained arrhythmia, torsades de pointes, tachycardia, atrioventricular block, QT prolongation syndrome or a family history of QT prolongation syndrome symptoms;\n9. . Patients with dysphagia, esophageal stenosis or gastrointestinal diseases that cause clinically significant symptoms or with a history of severe vomiting and diarrhea in the week prior screening;\n10. Patients who previously underwent surgery that would affect the absorption, distribution, metabolism and excretion of drugs, or had undergone major surgery or had incomplete healing of surgical incision within 6 months prior to the screening period; or planned to undergo surgery during the study period;\n11. History of drug, food, or environmental allergy, especially to components similar to the investigational product, or a known allergic constitution;\n12. Patients with symptomatic hemorrhoids or diseases accompanied by regular\u002Fongoing hematochezia, irritable bowel syndrome, and inflammatory bowel disease;\n13. History of congenital or acquired urinary tract stenosis, prostatic hyperplasia, or abnormal bladder function;\n14. Habitual diarrhea or average bowel movement frequency less than once daily;\n15. Alcoholics or regular drinkers within 6 months before screening, that is, drinking more than 14 units of alcohol per week, or alcohol breath test results \\> 0 mg\u002F100ml at screening, or drinkers within 48 hours before the use of the test drug, or unable to abstain from alcohol during the test;\n16. The average daily smoking amount in the 3 months before screening is greater than 5 cigarettes or habitual use of nicotine-containing products, or unable to abstain during the trial;\n17. Previous history of drug abuse or drug abuse, or positive urine drug abuse screening;\n18. Excessive consumption of tea, coffee and\u002For caffeine-rich beverages, grapefruit juice and other beverages that affect liver enzyme activity per day within 3 months before screening, or inability to abstain during the trial;\n19. Those with special requirements for diet or failing to comply with the unified diet;\n20. Those who plan to have strenuous exercise during the trial;\n21. Workers engaged in long-term exposure to radioactive conditions, or those with significant radioactive exposure;\n22. Blood loss or blood donation;\n23. Those with a history of fainting, blood, or difficult to collect blood or unable to tolerate venipuncture blood collection;\n24. Those who have participated in any clinical trial within 3 months prior to screening and have received investigational drugs or used investigational devices; or those who plan to participate in other clinical trials during this study;\n25. Those who have received vaccination within 4 weeks prior to screening or plan to receive vaccination during the trial to 1 month after the end of the trial.",true,"MALE","45 Years",{"count":299,"type":23},8,[165],"This is a phase 1, single-center, single-dose, open-label mass-balance study to evaluate radioactive recovery rate, radioactive PK characteristics, metabolite identification, and to observe the safety in healthy male subjects of \\[14C\\] LPM3770164.",[29],"2026-04-01",{"date":305,"type":42},"2026-04-08",{"date":307,"type":23},"2026-04-30",{"date":309,"type":23},"2026-07-30",{"name":311,"class":49},"Luye Pharma Group Ltd.",{"id":313,"slug":314,"hasResults":12,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":295,"sex":18,"minAge":195,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":24,"phases":322,"briefSummary":323,"conditions":324,"keywords":4,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":328,"completionDateStruct":329,"leadSponsor":331,"locationsCount":216},"100624435","autobiographical-memory-future-thought-and-eye-movements-in-huntingtons-disease-100624435","NCT07409597","Autobiographical Memory, Future Thought, and Eye Movements in Huntington's Disease","Mémoire Autobiographique, pensée Future et Mouvements OCulaires Dans la Maladie de Huntington - MAMOC-MH","MAMOC-MH","Inclusion criteria\n\nFor patients:\n\n* Adults at inclusion\n* Huntington's disease diagnosed and confirmed by genetic analysis\n* Patients in the presymptomatic stage of HD with a motor UHDRS score ≤ 5 and patients in symptomatic stages 1-2 of HD with a motor UHDRS score \\> 5 and a CFT between 6 \\\u003C CFT ≤ 13\n* Patients who have given their written informed consent or consent from a third party\n* Affiliated with or beneficiary of a social security system\n\nFor healthy controls:\n\nPre-inclusion criteria\n\n* Adults at inclusion\n* Individuals with no history of neurological disorders (interview and clinical examination)\n* Signature of informed consent to participate in the study\n* Affiliated with or beneficiary of a social security system\n* Matching in age (± 5 years), sex, and level of education with an HD patient included in the control group\n\nInclusion criteria\n\n• MMSE ≥ 24\u002F30",{"count":321,"type":23},80,[200],"Huntington's disease (HD) is a hereditary neurodegenerative disorder characterized by progressively worsening motor, cognitive, psychiatric, and behavioral deficits. Cognitive deficits occur early on, affecting in particular executive functions (inhibition, flexibility), decision-making, memory, attention (selective, sustained), perceptual and visuospatial skills, and information processing speed.\n\nMore specifically, memory deficits quickly affect different memory systems (short-term memory, long-term memory, etc.), including autobiographical memory. Autobiographical memory is usually defined as a system that stores all the information (semantic component) and specific memories (episodic component) specific to an individual, accumulated from an early age. Autobiographical memory is now considered essential to the construction of a sense of identity and continuity. It is also considered indispensable for projecting into the future, otherwise known as \"episodic future thinking,\" a fundamental human capacity that is both anticipatory and adaptive.\n\nAutobiographical memory deficits remain largely unexplored in HD, with only three studies identified in the international literature on the subject, one of which is actually based on the same neuropsychological data as another, adding a neuroanatomical analysis focused on autobiographical memory. These studies show that the autobiographical recollections of patients with HD are mainly descriptive recollections of personal events lacking in detail, and that the abnormalities appear to be linked to the progressive degeneration of a vast cortico-subcortical brain network comprising the medial temporal cortex, the frontal cortex, and the posterior striatal and parietal regions. Deficits in episodic future thinking have never been explored in HD. A better understanding of the mechanisms underlying this type of cognitive impairment (recalling personal memories and mentally simulating future personal events) remains a major challenge today in improving the care of patients with HD.\n\nSeveral recent studies have shown, in different pathological contexts (Alzheimer's disease, etc.), that the parallel use of neuropsychological tests (tasks and questionnaires) and an eye-tracking system allows for a much more accurate and in-depth examination of cognitive functions (for a review, see). In addition, eye movements, such as fixations and saccades, have been associated with the retrieval of autobiographical events . These movements better reflected the person's subjective experience, particularly with regard to the visual elements of mental imagery of recovered events. This suggests that the analysis of eye behavior could enrich the assessment of autobiographical memory, beyond the data provided by traditional tests.\n\nThe examination of eye movements is therefore, alongside neuropsychological testing, a promising non-invasive method for better understanding the characteristics of autobiographical memory in HD.\n\nThis project therefore aims to explore the autobiographical memory of HD patients by analyzing their eye activity during tasks involving the recall of personal events using standard neuropsychological tools. By identifying oculomotor markers associated with autobiographical memory disorders, this research could: (1) provide a better understanding of the neurocognitive profile of HD, (2) pave the way for more accurate diagnostic tools, and (3) form an important basis for the development of future interventions aimed at supporting memory function in this population.",[29,325],"Autobiographical Memory","2026-03-31",{"date":281,"type":42},{"date":303,"type":23},{"date":330,"type":23},"2029-04-01",{"name":332,"class":333},"University Hospital, Angers","OTHER_GOV",{"id":335,"slug":336,"hasResults":12,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":340,"eligibilityCriteria":341,"healthyVolunteers":295,"sex":18,"minAge":195,"maxAge":342,"enrollmentInfo":343,"targetDuration":4,"studyType":24,"phases":344,"briefSummary":346,"conditions":347,"keywords":353,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":216},"100564857","early-phase-1-imagemhtt-009--fih-evaluation-of-novel-mutant-huntingtin-pet-radioligand-11cchdi-00491009-100564857","NCT06634628","iMagemHTT-009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand [11C]CHDI-00491009","First in Human Adaptive Study to Investigate the Kinetic Properties of the Novel PET Radioligand [11C]CHDI-00491009 and Its Suitability for Quantification of Aggregated Mutant Huntingtin in the Brains of People With Huntington's Disease","iMagemHTT-009","Inclusion Criteria:\n\nPwHD HD-ISS Stages 2 and 3 and HC participants who:\n\n1. Are female or male adults, age 18-64 years old, inclusive.\n2. Have body mass index (BMI) between 19 and 35, inclusive.\n3. Have capacity to give full informed consent in writing and have read and signed the informed consent form (ICF).\n4. Are able to comply with study procedures, including fasting and blood sampling.\n5. Are able and willing to travel to the imaging center in Leuven, Belgium.\n6. Are willing to comply with the use of adequate contraceptive measures.\n\n   HD-ISS Stage 2 participants who:\n7. Have a huntingtin gene CAG expansion between 40 and 50, inclusive; and\n8. Are classified within HD-ISS Stage 2 per the HD-ISS criteria using HD-ISS Modified Stage calculator.\n9. Have a PIN score of 0.47 to 1.84 \\[prognostic index normed for HD (PIN) where PIN = (PIHD - 883)\u002F1044 where PIHD = 51 x TMS + (-34) x SDMT + 7 x Age x (CAG - 34) (TMS is the UHDRS Total Motor Score, and SDMT is the UHDRS Symbol Digit Modalities Test)\\].\n\nHD-ISS Stage 2 participants who:\n\n7\\. Have a huntingtin gene CAG expansion between 40 and 50, inclusive; and 8. Are classified within HD-ISS Stage 2 per the HD-ISS criteria using HD-ISS Modified Stage calculator.\n\n9\\. Have a PIN score of 0.47 to 1.84 \\[prognostic index normed for HD (PIN) where PIN = (PIHD - 883)\u002F1044 where PIHD = 51 x TMS + (-34) x SDMT + 7 x Age x (CAG - 34) (TMS is the UHDRS Total Motor Score, and SDMT is the UHDRS Symbol Digit Modalities Test)\\].\n\nHC participants who:\n\n13\\. Have no known family history of HD; or 14. Have a known family history of HD and have been tested for the huntingtin gene CAG expansion and are not at genetic risk for HD (CAG \\\u003C 36).\n\n15\\. Age match (+\u002F- 5 years) and biological sex match to each HD participant in Cohort 2 and Cohort 3 (except for Cohort 1, no matching).\n\nExclusion Criteria:\n\nPwHD HD-ISS Stages 2 and 3 and HC participants who:\n\n1. Are currently participating in, or are less than 30 days after completing participation in, other therapeutic or imaging studies.\n2. Have previously participated in a PET imaging study in the past 12 months that, cumulatively with the current study, will exceed annual regulatory limits for radiation exposure.\n3. Have any disease, condition, or concomitant medication that significantly compromises the function of the body systems and that, in the opinion of the Investigator, might interfere with the conduct of the study or its interpretation.\n4. Are pregnant and breastfeeding females.\n5. Have concomitant use of antiplatelet or anticoagulant therapy (inclusive of acetylsalicylic acid).\n6. Have a bleeding disorder.\n7. Have a needle phobia.\n8. Have any metal objects present in the body that are incompatible with MRI.\n9. Have metal objects present in the body that are compatible with MRI and are located in the head or neck.\n10. Have any clinically significant results on safety laboratory tests that, in the opinion of the Investigator, would either put the participant at risk or interfere with the conduct of the study or interpretation of data. These tests include, but are not limited to:\n\n    * a. positive results for HBsAg, HepC, HIV-1 or HIV-2 (will also be reported as required by local\u002Fnational regulations),\n    * b. clinically significant, abnormal results for safety laboratory tests.\n\n    PwHD participants who:\n11. If they are using any antidepressant, psychoactive, psychotropic or other medications or nutraceuticals used to treat HD, the use of inappropriate (e.g., non-therapeutically high) or unstable dose within 30 days prior to participation.\n\n    HC participants who:\n12. Have a family history of HD and have not been tested for the huntingtin gene (CAG) expansion.","64 Years",{"count":130,"type":23},[345],"EARLY_PHASE1","This is a FIH (first-in-human) study to evaluate the clinical utility of the radioligand \\[11C\\]CHDI-00491009 as a PET tracer that binds specifically to mutant huntingtin (mHTT) aggregates in Huntington's disease (HD).\n\nThe study is divided into three cohorts defined by the Huntington's Disease Integrated Staging System (HD-ISS): Cohort 1 - initial tracer validation (3 healthy controls (HCs)); Cohort 2 - target validation and test-retest variability (6 HD-ISS Stage 3 participants and 6 age and biological sex-matched HCs); Cohort 3 - target sensitivity (6 HD-ISS Stage 2 participants and 6 age and biological sex-matched HCs). An interim analysis (IA) will be conducted after the completion of each cohort, followed by a final analysis for the study.\n\nIn addition to imaging, exploratory biomarkers, including somatic instability index, soluble mHTT and total huntingtin (HTT), will be assessed. All participants with HD (PwHD) will have an additional blood sample drawn at the screening visit to assess the somatic instability index and will also be invited to provide an optional cerebrospinal fluid (CSF) sample for measurement of soluble mHTT and total HTT.",[29,31,348,349,350,351,36,352,169],"PET Tracer","Positron Emission Tomography","Radioligand","Imaging","Huntington's",[354,29,31,348,349,355,356,36,357,169],"iMagemHTT","radioligand","imaging","huntingtin","2026-03-12",{"date":360,"type":42},"2026-03-13",{"date":362,"type":42},"2026-02-24",{"date":364,"type":23},"2028-03",{"name":366,"class":215},"CHDI Foundation, Inc.",{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":295,"sex":18,"minAge":195,"maxAge":196,"enrollmentInfo":374,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":376,"conditions":377,"keywords":378,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":216},"100612396","evaluation-of-three-tests-to-assess-social-cognition-in-huntington-disease-100612396","NCT07253038","Evaluation of Three Tests to Assess Social Cognition in Huntington Disease","The Social-HD Study: A Cross-Sectional Observational Study of Social Cognition in Early Huntington Disease","Inclusion Criteria:\n\nInclusion criteria for persons with HD\n\n1. Clinical diagnosis of HD\n2. CAG repeat: 40 and more\n\nInclusion criteria for control group\n\n1\\. No heritage of HD or negative pre-symptomatic HD gene test\n\nExclusion Criteria:\n\nParticipants in both groups are excluded from the study if any of the following criteria apply:\n\n1. Dementia or MOCA\\\u003C19, The Mini Mental State Examination (MMSE) \\\u003C19\n2. Other neurological disorders\n3. Ongoing psychosis\n4. Ongoing alcohol\u002Fdrug addiction\n5. Other native language than Swedish\n6. Severe problems with vision and hearing",{"count":375,"type":23},40,"The goal of this observational study is to learn about the usefulness of a test of social functioning in persons with Huntington disease. Huntington disease affects motor function, psychological well-being and cognitive functions (\"thinking abilities\" such as paying attention, remembering and solving problems). It is also believed to affect important social functions, including the ability to understand others' intentions and emotions (social cognition). The test of interest in this study is called The Double Movie for the Assessment of Social Cognition-Multiple Choice (DMASC-MC) and will be compared to two other similar and well-known tests. The main question which the study aims to answer is:\n\n• Is DMASC-MC a useful tool for detecting problems with social functioning in adult persons with early Huntington disease? In the study, participants will meet with a medical doctor and a psychologist for assessment of different symptoms related to Huntington disease, including social functioning. Better methods for identifying problems with social functioning could help persons with Huntington disease and their families in mainly two ways. Firstly, it could increase their understanding of how the disease has affected them. Secondly, a better understanding of these problems could lead to better recommendations and interventions from medical teams, which would also benefit persons with Huntington disease and families.",[29],[379,380,381,382,383,384],"social cognition","apathy","cognition","depression","total functional capacity","total motor score","2026-03-10",{"date":387,"type":42},"2026-03-11",{"date":389,"type":42},"2025-12-01",{"date":391,"type":23},"2027-09-01",{"name":393,"class":215},"Region Skane",{"id":395,"slug":396,"hasResults":12,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":400,"eligibilityCriteria":401,"healthyVolunteers":12,"sex":18,"minAge":402,"maxAge":140,"enrollmentInfo":403,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":405,"conditions":406,"keywords":407,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":216},"100558082","cognitive-assessment-tools-for-huntingtons-disease-100558082","NCT06546488","Cognitive Assessment Tools for Huntington's Disease.","Cognitive Assessment Tools for Individuals With Huntington's Disease.","CAT-HD","Inclusion Criteria:\n\n1. Males and females aged 30-65 (inclusive) at the time of signing the informed consent form.\n2. Genetic diagnosis of HD as defined by a CAG repeat size ≥ 40.\n3. A clinical diagnosis of HD as defined by a Diagnostic Confidence Level (DCL) of 4.\n4. Vision and hearing sufficient for compliance with tests.\n5. On a stable dose of medications for 30 days prior to the time of signing the informed consent form.\n\nExclusion Criteria:\n\n1. Age of symptom onset less than 19 years old or greater than 60 years old.\n2. Any serious neurological disorder aside from HD, including but not limited to Alzheimer's disease, Parkinson's disease, Frontotemporal dementia, Lewy body dementia, Amyotrophic Lateral Sclerosis, Traumatic Brain Injury… etc. that in the opinion of the investigator is clinically significant.\n3. Any ongoing serious medical condition that in the opinion of the investigator is clinically significant. This includes autoimmune diseases, ongoing treatment for cancer, congestive heart failure, severe pulmonary disease, or any history of a seizure disorder (including the need to take anti-epileptics to prevent seizure).\n4. Subjects who are pregnant or breast feeding\n5. Subjects with a history of a learning disability.\n6. Subjects who are unable to provide consent.","30 Years",{"count":404,"type":23},76,"The purpose of the current proposal is to expand understanding of two currently available cognitive tools that are not typically used in Huntington Disease (HD) clinical trials that might be useful both for initial screening and for clinical trial application. One is the Coding Test and the other is the Self-Administered Gerocognitive Examination (SAGE). Both the Coding Test and the SAGE have been used for assessments of individuals with other neurodegenerative diseases, including Alzheimer's Disease, Parkinson's Disease and Lewy Body Disease, but data is lacking on their use in individuals with HD.",[29],[408,409,29],"Self-Administered Gerocognitive Examination (SAGE)","Coding","2026-02-26",{"date":412,"type":42},"2026-03-02",{"date":414,"type":42},"2025-06-20",{"date":416,"type":23},"2027-12-01",{"name":418,"class":215},"Ohio State University",{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":425,"eligibilityCriteria":426,"healthyVolunteers":295,"sex":18,"minAge":195,"maxAge":4,"enrollmentInfo":427,"targetDuration":4,"studyType":24,"phases":429,"briefSummary":430,"conditions":431,"keywords":432,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":216},"100363453","study-of-bdnf-pathway-biomarkers-in-the-cerebrospinal-fluid-in-patients-with-huntingtons-disease-100363453","NCT04012411","Study of BDNF Pathway Biomarkers in the Cerebrospinal Fluid in Patients With Huntington's Disease","Study of Brain Derived Neurotrophic Factor (BDNF) Pathway Biomarkers in the Cerebrospinal Fluid in Patients With Huntington's Disease","LCR-MH","Inclusion Criteria:\n\n* General inclusion criteria:\n\n  * age ≥ 18 years-old\n  * national health insurance cover\n* Patients inclusion criteria:\n\n  * genetically confirmed Huntington's disease diagnosis (≥ 35 CAG repeat in HTT gene exon 1)\n  * written informed consent\n  * only for patients \"with lumbar puncture (LP)\": patient agreement for LP\n* Control inclusion criteria:\n\n  * anterior LP for medical reason with consent for biobank \"Neuro\" with following samples present in this biobank : 2 mL blood + 0.5 mL plasma + 0.5 mL cerebrospinal fluid\n  * information and non-opposition for the finality of this biobank\n  * paired by age with a patient (+\u002F- 5 years difference)\n\nExclusion Criteria:\n\n* General exclusion criteria:\n\n  * protected by law\n* Patients exclusion criteria:\n\n  * Huntington's disease stage too Evolved that may interfere with cognitive evaluations or MRI\n  * contraindications to brain MRI\n  * only for patients \"with LP\": contraindications to LP\n  * incapacity to give informed consent\n* Control exclusion criteria:\n\n  * neurodegenerative of inflammatory central nervous system pathology",{"count":428,"type":23},135,[200],"Huntington disease (HD, 1.3\u002F10 000) is an autosomal dominant disease due to an abnormal expansion of CAG triplets in HTT gene.\n\nSeveral pathophysiological mechanisms have been evoked, including an alteration of the signaling pathway of the Brain Derived Neurotrophic Factor (BDNF), a neurotrophic factor involved in the survival of neurons (striatal and hippocampal) and synaptic plasticity. BDNF is synthesized at the level of cortical neurons and transported, through the axonal transport in which the Htt is involved, to the nerve endings; it's then secreted in response to excitatory synaptic activity, especially at the level of glutamatergic synapses. Besides, at the postsynaptic level it binds with great specificity to TrkB receptors (tropomyosin-related kinase receptors B) with a neuroprotective effect on dendritic and axonal growth and an increase in synaptic plasticity, especially at the level of the striatum and the hippocampus.\n\nBDNF is decreased in the brain of animal models, as well as in patients with HD; the alteration of this pathway would occur in the early stages of the disease.\n\nIn the context of concomitant multiple treatments, the BNDF pathway may be one of the therapeutic targets of HD.\n\nMoreover, in HD it remains essential to detect biological markers representative of the different pathogenic pathways that can be tested in vivo in humans to confirm the hypotheses developed at the level of basic research; these biomarkers could subsequently become biomarkers of disease progression and\u002For biomarkers of therapeutic efficacy of potential targeted treatments.\n\nTherefore, this study aims to characterize potential biomarkers of the BNDF pathway in plasma and CSF in subjects with HD and to confirm the importance of this pathogenic mechanism in vivo in humans.",[29],[29,433,434,435,436],"CSF","Biomarkers","BDNF","P42","2026-02-09",{"date":439,"type":42},"2026-02-12",{"date":441,"type":42},"2020-03-03",{"date":443,"type":23},"2027-09",{"name":445,"class":215},"University Hospital, Montpellier",{"id":447,"slug":448,"hasResults":12,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":4,"eligibilityCriteria":452,"healthyVolunteers":12,"sex":18,"minAge":195,"maxAge":453,"enrollmentInfo":454,"targetDuration":4,"studyType":24,"phases":456,"briefSummary":457,"conditions":458,"keywords":459,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":216},"100580895","home-based-tdcs-transcranial-direct-current-stimulation-for-cognitive-and-behavioral-symptoms-in-huntingtons-disease-100580895","NCT06843252","Home-based TDCS (Transcranial Direct Current Stimulation) for Cognitive and Behavioral Symptoms in Huntington's Disease","Home-based TDCS for Cognitive and Behavioral Symptoms in Huntington's Disease: a Pilot Feasibility and Mechanistic Study","Inclusion Criteria:\n\n1. individuals aged 18-85 years with confirmed HD mutation and\u002For established family history alongside typical symptoms (i.e., chorea) of HD;\n2. early (stages 1 and 2) or moderate (stage 3) stages according to Shoulson-Fahn criteria, also known as the UHDRS total functional capacity (TFC) scale (Bates, Tabrizi, and Jones 2014);\n3. exhibit mild to moderate behavioral symptoms defined by severity scores in the PBA-S between 1 and 3 for any of the evaluated symptoms and no symptoms with a severity score of 4;\n4. stable doses of medications for at least one month.\n5. Ability of subject to understand and the willingness to sign a written informed consent document.\n6. Have a caregiver willing to be present during tDCS sessions and answer questionnaires.\n\nCaregiver\n\n1. An adult who serves as an unpaid caregiver for an individual enrolled in the study as interpreted by the PI or delegate physician.\n2. Adequate cognitive capacity to provide verbal consent to participate in the caregiver arm of the study.\n3. Adequate reading, writing, hearing, and verbal capacity to provide collateral information about the study participant as well as answer questions related to their health and care.\n\nExclusion Criteria:\n\n1. Unstable medical conditions (e.g. unstable angina, uncontrolled diabetes and hypertension, advanced cancer, etc.);\n2. History of epilepsy;\n3. Clinical diagnosis of major cognitive disorder (i.e., dementia);\n4. Have risk of suicidal behavior, defined as any suicidal behavior or suicidal ideation of type 4 (active suicidal ideation with some intent to act, without specific plan) or type 5 (active suicidal ideation with specific plan and intent) based on the Columbia-Suicide Severity Rating Scale (C-SSRS) in the 3 months prior to screening (Posner et al. 2011);\n5. Being an active participant in other therapeutic clinical trial;\n6. Determined to be incapable of consent per PMH or via assessment by the study staff at time of consent.\n7. Participant has a pacemaker or any other implanted device\u002Fmaterial contraindicated in the use of tDCS per current labeling requirements.\n\nCaregiver\n\n1\\. Any individual who does not meet all the inclusion criteria","85 Years",{"count":455,"type":23},16,[200],"The researchers hope to find out effects of transcranial direct current stimulation (tDCS) sessions on the behavioral symptoms of Huntington's Disease. If participants are eligible to continue, they will be provided a device to administer the tDCS for 30 minutes each day and be asked to answer questions with the study staff . Participants will be asked to return to the study center for follow ups and to undergo additional cognitive tests and questionnaires. Participants will also be asked to answer questionnaires via a web conferencing platform (Zoom) during the course of the study. Caregivers of the participants will be asked to answer questionnaires to collect more information about the participants.",[29],[460,461,462,463],"Transcranial direct current stimulation","Home-based","Behavioral symptoms","Cognitive symptoms","2026-02-06",{"date":466,"type":42},"2026-02-11",{"date":468,"type":42},"2025-09-02",{"date":470,"type":23},"2027-06",{"name":472,"class":215},"The University of Texas Health Science Center at San Antonio",{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":18,"minAge":195,"maxAge":479,"enrollmentInfo":480,"targetDuration":4,"studyType":24,"phases":481,"briefSummary":482,"conditions":483,"keywords":484,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":486,"startDateStruct":487,"completionDateStruct":489,"leadSponsor":491,"locationsCount":216},"100464342","home-based-transcranial-direct-current-stimulation-open-trial-for-behavioral-and-cognitive-symptoms-in-huntingtons-disease-100464342","NCT05326451","Home-based Transcranial Direct Current Stimulation Open Trial for Behavioral and Cognitive Symptoms in Huntington's Disease","Participant:\n\nInclusion Criteria:\n\n* confirmed HD mutation carriers and\u002For established family history alongside typical symptoms (i.e. chorea) of HD;\n* early (stages 1 and 2) or moderate (stage 3) stages according to Shoulson-Fahn\n* exhibit mild to moderate behavioral symptoms defined by severity scores in the PBA-S between 1 and 3 for any of the evaluated symptoms and no symptoms with a severity score of 4\n* stable doses of medications for at least one month\n* Have a caregiver willing to be present during tDCS sessions and answer questionnaires.\n\nExclusion Criteria:\n\n* unstable medical conditions\n* history of epilepsy\n* metallic objects in the brain\n* Have a caregiver willing to be present during tDCS sessions and answer questionnaires.\n* clinical diagnosis of major cognitive disorder or dementia\n* Have risk of suicidal behavior, defined as any suicidal behavior or suicidal ideation of type 4 or type 5 based on the Columbia-Suicide Severity Rating Scale (C-SSRS) in the 3 months prior to screening\n* simultaneous participation in other clinical trial\n* Individuals determined to be incapable of consent per past medical history or via assessment by the study staff at time of consent.\n\nCaregiver:\n\nInclusion Criteria:\n\n-willingness to participate in the study\n\nExclusion Criteria:\n\n-motor\u002Fcognitive symptoms related to Alzheimer's disease or Huntington's disease that might impair the ability to assist the participant during the research study.","80 Years",{"count":94,"type":23},[200],"The purpose of this study is to assess feasibility, acceptability, and safety of providing transcranial direct current stimulation( tDCS) to Huntingtons Disease (HD) patients in the early to middle stages and to assess the efficacy of tDCS for HD-related behavioral, cognitive and other symptoms",[29],[485],"transcranial direct current stimulation",{"date":466,"type":42},{"date":488,"type":42},"2023-06-21",{"date":490,"type":23},"2026-12-31",{"name":492,"class":215},"The University of Texas Health Science Center, Houston",{"id":494,"slug":495,"hasResults":12,"nctId":496,"briefTitle":497,"officialTitle":498,"acronym":4,"eligibilityCriteria":499,"healthyVolunteers":295,"sex":18,"minAge":195,"maxAge":4,"enrollmentInfo":500,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":502,"conditions":503,"keywords":518,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":536,"locationsCount":216},"100303705","retinal-imaging-in-neurodegenerative-disease-100303705","NCT03233646","Retinal Imaging in Neurodegenerative Disease","Evaluating the Retinal and Choroidal Microvasculature and Structure Using Multimodal Retinal and Choroidal Imaging in Neurodegenerative Disease: iMIND Research Study","Inclusion Criteria:\n\n* Adults with neurodegenerative disease ((MCI, PD, AD, FTD, DLB, ALS, MS, HD, TBI, concussion, PTSD and other neurodegenerations as well as Down Syndrome)\n* Adults without neurodegenerative disease\n\nExclusion Criteria:\n\n* Inability to cooperate with or complete testing or other neurologic or age- related ocular conditions that would impact image acquisition.\n* Eyes that have had intraocular surgery, other than cataract surgery.\n\nIf two eyes satisfy the inclusion criteria, both eyes will be included in the study. If one eye satisfies the inclusion criteria, the eye that qualifies will be included in the study.",{"count":501,"type":23},2000,"This study aims to develop and evaluate biomarkers using non-invasive optical coherence tomography (OCT) and OCT angiography (OCTA) as well as ultra-widefield (UWF) fundus photography to assess the structure and function of the retinal and choroidal microvasculature and structure in persons with mild cognitive impairment (MCI) and Alzheimer's Disease (AD), Parkinson's Disease (PD), or other neurodegenerative disease, diseases as outlined.",[504,505,506,507,29,508,509,510,511,512,513,514,515,516,517],"Alzheimer's Disease","Mild Cognitive Impairment","Parkinson's Disease","Multiple Sclerosis","Lewy Body Dementia","Frontotemporal Dementia","Amyotrophic Lateral Sclerosis (ALS)","APOE-4 Positive","Traumatic Brain Injury","Concussion","Post-Traumatic Stress Disorder","Down Syndrome","Neuro-Degenerative Disease","Normal Cognition",[519,520,521,522,523,524,525,526,527,528,529],"OCT angiography (OCTA)","Optical Coherence Tomography (OCT)","Vessel Density","Superficial Capillary Plexus","Retinal microvasculature","Scanning Laser Ophthalmoscopy","Ultra-widefield (UWF) Imaging","Perfusion Density","Retinal Nerve Fiber Layer","Ganglion Cell Inner Plexiform Layer","Choroidal Vascularity Index","2026-02-02",{"date":532,"type":42},"2026-02-04",{"date":534,"type":42},"2017-07-20",{"date":490,"type":23},{"name":537,"class":215},"Duke University",{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":543,"acronym":544,"eligibilityCriteria":545,"healthyVolunteers":12,"sex":18,"minAge":195,"maxAge":546,"enrollmentInfo":547,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":549,"conditions":550,"keywords":551,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":557,"lastUpdatePostDateStruct":558,"startDateStruct":560,"completionDateStruct":562,"leadSponsor":563,"locationsCount":216},"100575604","hinting-task-for-huntingtons-disease-100575604","NCT06774443","Hinting Task for Huntington's Disease","Sensitivity of the Hinting Task in Patients With Huntington's Disease","HT-HD","Inclusion Criteria:\n\n* Confirmed diagnosis of Huntington's disease via CAG-repeat length analysis, minimum of 40 repeats\n* Between 18 and 74 years of age\n* Dutch speaking\n\nExclusion Criteria:\n\n* Presence of serious psychiatric disorders or other neurological comorbidities","74 Years",{"count":548,"type":23},52,"Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder, characterized by movement disorders, behavioural disorders and cognitive decline. Especially the behavioural and cognitive symptoms of the disease lead to significant disability and burden for patients as well as caregivers. One of the cognitive domains affected by HD is social cognition. Social cognition is the ability to perceive, interpret and respond correctly to social information. Aspects of social cognition are emotion recognition, perspective taking (Theory of Mind), and emapathy. Social cognition problems can be related to behavioural problems, but to be able to study this relationship, it is important to be able to reliable measure social cognition impairments. There are a few social cognition tests available, but often they are not normd and validated for use in a Dutch neurological population. There is a lack of sensitive, simple, tests for measuring Theory of Mind in patients with HD. A promising test, that already has been proven valid in a psychiatric population, is the Hinting Task. The Hinting Task measures theory of mind through indirect speech, The Hinting task is a social cognition test, where hints are implicitly given in speech, which resembles what patients and caregivers frequently report as difficult in HD. The Hinting Task has already been translated into Dutch and is already being used in clinical parctice, but its sensitivity has not been studied yet in a neurological population. The aim of this study is to assess if the Hinting Task is sensitive in patients with HD and to relate the Hinting Task to other (social) cognitive measures, demographical characteristics and disease characteristics.",[29],[552,553,554,555,556],"Social Cognition","Theory of Mind","Hinting Task","Huntington","CAG repeat","2026-01-27",{"date":559,"type":42},"2026-01-29",{"date":561,"type":42},"2025-09-01",{"date":490,"type":23},{"name":564,"class":215},"University Medical Center Groningen",{"id":566,"slug":567,"hasResults":12,"nctId":568,"briefTitle":569,"officialTitle":570,"acronym":571,"eligibilityCriteria":572,"healthyVolunteers":295,"sex":18,"minAge":59,"maxAge":140,"enrollmentInfo":573,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":575,"conditions":576,"keywords":578,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":581,"completionDateStruct":582,"leadSponsor":584,"locationsCount":216},"100593766","digital-measures-for-clinical-trial-endpoints-in-huntingtons-disease-100593766","NCT07010705","Digital Measures for Clinical Trial Endpoints in Huntington's Disease","Digital Measures for Clinical Trial Endpoints in Huntington's Disease (MEND-HD)","MEND-HD","Inclusion Criteria:\n\nInclusion Criteria for participants with adult-onset HD:\n\n* Age of 25-65 years.\n* Genetically confirmed HD with CAG \\>= 40 (HD-ISS Stage 2 or mild\u002Fmoderate Stage 3)\n* English speaking.\n\nInclusion Criteria for control participants:\n\n* Age of 25-65 years.\n* English speaking.\n\nInclusion Criteria for support persons:\n\n* Self-identified support person or family member of the enrolled participants with HD.\n* 18 years or older\n* English speaking.\n\nExclusion Criteria:\n\n* Diagnosis of juvenile-onset HD.\n* History of co-morbid neurological disease or disorders such as stroke, multiple sclerosis, or moderate to severe\n* Traumatic Brain Injury.\n* Use of an assistive device for ambulation.\n* Montreal Cognitive Assessment (MoCA) score of 18 or lower\n* Acute or chronic medical conditions that significantly impact gait or mobility in the opinion of the investigator, e.g. ankle sprain or fracture, or any orthopedic,\n* cardiovascular or psychiatric disease.\n* Pregnancy\n* Cannot be enrolled into a blinded intervention trial at Baseline",{"count":574,"type":23},100,"MEND-HD is a longitudinal study evaluating the feasibility of passive monitoring of gait and chorea in patients with HD and the meaningfulness of these outcomes for patients with HD and their care partners\u002Fsupport persons.\n\nParticipants will take part in four virtual visits with study investigators to answer survey questions on movement and cognition, perform in-home movement assessments, and take part in an interview regarding the meaningfulness of gait and chorea in their daily lives.\n\nParticipant and care partner interviews will be used for symptom mapping and qualitative data analysis to assess the relevance and impact of the targeted symptoms on the participant's daily life.\n\nThe study may be extended to 3 years to include yearly visits.",[29,577],"Healthy",[29],"2026-01-25",{"date":557,"type":42},{"date":414,"type":42},{"date":583,"type":23},"2026-09-30",{"name":585,"class":215},"University of Rochester",{"id":587,"slug":588,"hasResults":12,"nctId":589,"briefTitle":590,"officialTitle":590,"acronym":591,"eligibilityCriteria":592,"healthyVolunteers":295,"sex":18,"minAge":59,"maxAge":140,"enrollmentInfo":593,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":595,"conditions":596,"keywords":597,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":602,"startDateStruct":604,"completionDateStruct":606,"leadSponsor":608,"locationsCount":610},"100617235","multi-modal-digital-monitoring-of-disease-symptoms-huntingtons-disease-100617235","NCT07315984","Multi-Modal Digital Monitoring of Disease Symptoms Huntington's Disease","BioDigit HD-02","Inclusion Criteria:\n\n* Male or female, aged 25-65 years\n* For HD participants: Genetically diagnosed with HD\n* Fluent in English (able to speak and read).\n* Ambulatory without the need for a walking aid.\n* Able to independently perform all study activities safely, as determined by the investigator.\n* Willing and able to provide informed consent and comply with all study procedures.\n\nFor control participants:\n\n* Male or female, aged 25-65 years\n* Clinically assessed to be in good health, with no evidence of neurological disorders that could cause involuntary movements or gait disturbances\n\nExclusion Criteria:\n\n* Diagnosis of juvenile-onset HD.\n* Individuals who are non-ambulatory.\n* Individuals with a neurological, medical, or psychiatric condition that, in the investigator's judgment, would interfere with safe participation in study activities.\n* Montreal Cognitive Assessment (MoCA) score of 18 or lower\n* Pregnant individuals, due to potential changes in gait and physical activity during pregnancy.\n* Cannot be enrolled into a blinded intervention trial at baseline.",{"count":594,"type":23},75,"The objective of the study is to validate the use of wearable sensors and digital health technologies for monitoring disease activity in Huntington's Disease (HD). Healthy subjects, as well as subjects with documented diagnosis of HD will be screened and recruited at University of Rochester Medical Center and Vanderbilt University Medical Center to participate in this 12-month observational study. There will be a total of 5 visits every approximately 3 months.\n\nIn each study visit, participants will complete several Patient Reported Outcomes (PROs), Clinical Reported Outcomes, complete a series of Digital Assessments (Speech, Cognitive, Motor, and Finger Tapping). Participants will be provided with a pendant, wrist, and ankle sensors to monitor their daily physical activities for 7 days after each study visit. Participants will also be provided with a tablet to complete digital assessments (Speech, Cognitive, Motor, and Finger Tapping) on monthly basis at home.",[29],[598,599,600],"huntington disease","wearable sensors","digital health","2025-12-31",{"date":603,"type":42},"2026-01-05",{"date":605,"type":23},"2026-01-31",{"date":607,"type":23},"2028-12-31",{"name":609,"class":49},"BioSensics",2,{"id":612,"slug":613,"hasResults":12,"nctId":614,"briefTitle":615,"officialTitle":616,"acronym":617,"eligibilityCriteria":618,"healthyVolunteers":12,"sex":18,"minAge":195,"maxAge":4,"enrollmentInfo":619,"targetDuration":4,"studyType":24,"phases":621,"briefSummary":622,"conditions":623,"keywords":624,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":629,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":635,"locationsCount":216},"100547975","study-to-evaluate-music-therapy-on-irritability-and-impulsivity-in-patients-with-huntingtons-disease-music-hd-100547975","NCT06414967","Study to Evaluate Music Therapy on Irritability and Impulsivity in Patients With Huntington's Disease (MUSIC-HD)","Pilot Study Evaluating the Benefits of Music Therapy Combined With Conventional Treatment on Irritability and Impulsivity in Patients With Huntington's Disease (MUSIC-HD)","MUSIC-HD","Inclusion Criteria:\n\n* Age \\>= 18 years\n* Huntington disease genetically confirmed by the presence of at least 35 repeats of the CAG triplet in exon 1 of the HTT gene\n* UHDRS (Unified Huntington's disease Rating Scale) score \\\u003C= 5 with a diagnostic confidence score =4\n* Absence of significant cognitive impairment MoCA \\>=24\n* Stable drug therapy in the 28 days prior inclusion and during the study\n* Without legal tutors or subordination\n* Affiliated to a health insurance system as required by the French law on biomedical research\n* Written informed consent for participation in the study\n\nExclusion Criteria:\n\n* Inability to give free and informed consent for study participation\n* Significant hearing impairment\n* Participating to another study the day of enrollement\n* Persons benefiting from enhanced protection, i.e.persons deprived of their liberty by a judicial or administrative decision, adults under legal and finally patients in a vital emergency situation.",{"count":620,"type":23},15,[200],"The study is an open-label clinical trial evaluating whether music therapy combined with conventional management reduces irritability and impulsivity in 15 patients with early-stage Huntington's disease. This pilot study aims to show the interest of alternative non-pharmacological measures such as a digital music therapy tool, adapted to an audience of Huntington's patients, to help manage the psychobehavioral symptoms frequently observed in this affection, and to avoid breakdowns due to caregiver exhaustion.",[29],[625,626,627],"Music Therapy","Irritability","Impulsivity","2025-12-19",{"date":630,"type":42},"2025-12-29",{"date":632,"type":42},"2024-10-15",{"date":634,"type":23},"2026-10",{"name":636,"class":215},"Poitiers University Hospital",{"id":638,"slug":639,"hasResults":12,"nctId":640,"briefTitle":641,"officialTitle":641,"acronym":4,"eligibilityCriteria":642,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":643,"targetDuration":4,"studyType":24,"phases":645,"briefSummary":646,"conditions":647,"keywords":649,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":656,"lastUpdatePostDateStruct":657,"startDateStruct":659,"completionDateStruct":660,"leadSponsor":662,"locationsCount":216},"100609366","modification-of-threat-interpretation-bias-to-reduce-anxiety-in-neurodegenerative-movement-disorders-aim-3-100609366","NCT07213648","Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)","Inclusion Criteria:\n\n* Clinical diagnosis of Huntington's disease or Parkinson's disease (genetic diagnosis of HD also acceptable)\n* With anxiety symptoms (NeuroQoL Anxiety ≥12)\n\nExclusion Criteria:\n\n* Cognitive decline precluding ability to consent or complete the intervention (MoCA 5 min\u002Ftelephone ≤11)\n* Unable to read and understand English\n* Does not have regular access to an internet-connected device, capable of downloading and installing the mobile application (i.e., tablet or iPhone running iOS 10 or later or an Android phone running Android 5.0 or later)\n* Not located in the USA\n* \\\u003C21 years old\n* Active suicidality based on the answer \"yes\" to questions 4, 5, or 6b of the Columbia-Suicide Severity Rating Scale (Screen version)",{"count":644,"type":23},136,[200],"The purpose of this study is to assess preliminary efficacy of a tailored cognitive bias modification for interpretation (CBM-I) app for reducing anxiety in Huntington's disease and Parkinson's disease.",[29,648],"Parkinson Disease",[650,651,652,653,654,555,655],"CBM-I","cognitive bias modification","interpretation bias","anxiety","mobile app","Parkinson","2025-11-20",{"date":658,"type":42},"2025-11-21",{"date":656,"type":42},{"date":661,"type":23},"2026-09",{"name":663,"class":215},"University of Virginia",{"id":665,"slug":666,"hasResults":12,"nctId":667,"briefTitle":668,"officialTitle":668,"acronym":669,"eligibilityCriteria":670,"healthyVolunteers":12,"sex":18,"minAge":195,"maxAge":4,"enrollmentInfo":671,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":672,"conditions":673,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":674,"lastUpdatePostDateStruct":675,"startDateStruct":677,"completionDateStruct":679,"leadSponsor":681,"locationsCount":216},"100552654","longitudinal-endpoint-assessment-of-disease-burden-in-hd-100552654","NCT06475898","Longitudinal Endpoint Assessment of Disease Burden in HD","LEAD-HD","Inclusion Criteria:\n\n* Be 18 years of age or older;\n* Be willing and able to provide informed consent electronically;\n* Self-report, when answering as a participant, that you have been diagnosed with HD by a doctor, or have undergone genetic testing and been found to carry the gene mutation responsible for HD but have not been clinically diagnosed with HD (prodromal HD);\n* Have the ability to answer online questions or direct someone else to enter answers for them;\n* Have the ability to ambulate independently and take care of some of your personal needs;\n* Have the ability to read and understand English;\n* Be willing to create a unique identifier based on personal demographic information;\n* Reside in the United States or its territories. Surveys can only be completed in the US. If you move outside of the US, you will no longer be able to participate;\n* Own or have access to an electronic device and secure internet connectivity\n\nExclusion Criteria:\n\n\\-",{"count":104,"type":23},"LEAD-HD is intended to collect and analyze self-reported health information from individuals with Huntington Disease (HD) or prodromal HD participating in a 24-month longitudinal natural history study using remote technologies.",[29],"2025-09-09",{"date":676,"type":42},"2025-09-10",{"date":678,"type":42},"2024-06-25",{"date":680,"type":23},"2026-12",{"name":682,"class":683},"Huntington Study Group","NETWORK"]